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PDE-5 Inhibitors and the Increase Risk of Nonarteritic Anterior Ischemic Optic 
Neuropathy in Males with Erectile Dysfunction 
Abstract 
Background: PDE-5 inhibitors are effective treatments for erectile dysfunction and are one of the best 
selling drugs. Like most drugs they have side effects, and permanent vision loss due to nonarteritic 
anterior ischemic optic neuropathy (NAION) has been reported with the ingestion of these medications. 
Several case reports have shown a correlation between the two, but with lack of clinical trials there is no 
clear evidence of its existence. Can PDE-5 inhibitors increase the risk of developing NAION in males with 
erectile dysfunction? 
Methods: An exhaustive literature search using MEDLINE-Ovid, MEDLINE-PubMed, Web of Science, 
ClinicalKey, and CINAHL was performed using keywords: PDE-5 inhibitors, ischemic optic neuropathy, and 
NAION. These were screened with eligibility criteria. The resulting study and case reviews were then 
appraised and assessed for quality with GRADE. 
Results: One observational study and two case reviews were included in this systematic review. The 
observational study looked at 40 cases with intermittent PDE-5 inhibitor exposure in the 30 days prior to 
NAION onset. This study showed a twofold-increased risk of acute NAION within 5 half-lives of PDE-5 
inhibitor use. The case reviews revealed the same results, but with co-morbidities. 
Conclusion: PDE-5 inhibitors have been successful in providing relief to patients who suffer from erectile 
dysfunction; however, the permanent loss of vision is alarming, and needs to be further investigated. 
Additional research into the effects of this medication is essential to healthcare providers when they 
decide to prescribe this drug. 
Keywords: PDE-5 inhibitor, NAION, and ischemic optic neuropathy. 
Degree Type 
Capstone Project 
Degree Name 
Master of Science in Physician Assistant Studies 
Keywords 
PDE-5 inhibitor, NAION, and ischemic optic neuropathy 
This capstone project is available at CommonKnowledge: https://commons.pacificu.edu/pa/628 
Copyright and terms of use 
If you have downloaded this document directly from the web or from CommonKnowledge, see 
the “Rights” section on the previous page for the terms of use. 
If you have received this document through an interlibrary loan/document delivery service, the 
following terms of use apply: 
Copyright in this work is held by the author(s). You may download or print any portion of this 
document for personal use only, or for any use that is allowed by fair use (Title 17, §107 U.S.C.). 
Except for personal or fair use, you or your borrowing library may not reproduce, remix, 
republish, post, transmit, or distribute this document, or any portion thereof, without the 
permission of the copyright owner. [Note: If this document is licensed under a Creative 
Commons license (see “Rights” on the previous page) which allows broader usage rights, your 
use is governed by the terms of that license.] 
Inquiries regarding further use of these materials should be addressed to: CommonKnowledge 
Rights, Pacific University Library, 2043 College Way, Forest Grove, OR 97116, (503) 352-7209. 
Email inquiries may be directed to:.copyright@pacificu.edu 
 - 1 -  14 March 2017 
 
PDE-5 Inhibitors and the Increase Risk of Nonarteritic Anterior Ischemic Optic 
Neuropathy in Males with Erectile Dysfunction 
 
 
 
  
 
 
Shayne Ahwah 
 
 
 
 
 
 
 
 
 
 
 
A Clinical Graduate Project Submitted to the Faculty of the 
School of Physician Assistant Studies 
Pacific University 
Hillsboro, OR 
For the Masters of Science Degree, August 12, 2017 
Faculty Advisor: Craig Turner, M.D. 
Clinical Graduate Project Coordinator: Annjanette Sommers, PA-C, MS 
 
 
 - 2 -  14 March 2017 
 
Biography 
 
Shayne Ahwah was born in Kailua, Hawaii and did her undergraduate degree at the 
University of Nevada, Reno. She double majored in Biochemistry and Neuroscience. 
After completion of her degree, she worked in a Neuro-Ophthalmology Clinic as a 
technician for 5 years, to gain more medical experience. The experience at the clinic 
influenced the idea for the topic of this paper, and she hopes to practice as a Physician 
Assistant in Neurology or Emergency Medicine.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 3 -  14 March 2017 
 
Acknowledgements 
 
 To my family and friends:  Thank you for helping me to succeed and for 
supporting me through this journey. The best is yet to come! 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 4 -  14 March 2017 
Abstract 
Background: PDE-5 inhibitors are effective treatments for erectile dysfunction and are 
one of the best selling drugs. Like most drugs they have side effects, and permanent 
vision loss due to nonarteritic anterior ischemic optic neuropathy (NAION) has been 
reported with the ingestion of these medications. Several case reports have shown a 
correlation between the two, but with lack of clinical trials there is no clear evidence of 
its existence. Can PDE-5 inhibitors increase the risk of developing NAION in males with 
erectile dysfunction?  
 
Methods: An exhaustive literature search using MEDLINE-Ovid, MEDLINE-PubMed, 
Web of Science, ClinicalKey, and CINAHL was performed using keywords: PDE-5 
inhibitors, ischemic optic neuropathy, and NAION. These were screened with eligibility 
criteria.  The resulting study and case reviews were then appraised and assessed for 
quality with GRADE.  
 
Results:  One observational study and two case reviews were included in this systematic 
review. The observational study looked at 40 cases with intermittent PDE-5 inhibitor 
exposure in the 30 days prior to NAION onset. This study showed a twofold-increased 
risk of acute NAION within 5 half-lives of PDE-5 inhibitor use. The case reviews 
revealed the same results, but with co-morbidities.  
 
Conclusion:  PDE-5 inhibitors have been successful in providing relief to patients who 
suffer from erectile dysfunction; however, the permanent loss of vision is alarming, and 
needs to be further investigated. Additional research into the effects of this medication is 
essential to healthcare providers when they decide to prescribe this drug.  
 
Keywords: PDE-5 inhibitor, NAION, and ischemic optic neuropathy.  
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PDE-5 Inhibitors and the Increase Risk of Nonarteritic Anterior Ischemic Optic 
Neuropathy in Males with Erectile Dysfunction 
BACKGROUND 
Erectile dysfunction (ED) is a disorder that occurs during sexual stimulation that 
prevents the formation of an erection. Pharmaceutical companies developed a drug class, 
known as PDE-5 inhibitors, to aid in this issue. PDE-5 inhibitors release nitric oxide in 
the corpora cavernosa during sexual stimulation, which causes smooth muscle relaxation, 
vasodilation, and increased blood flow into the spongy tissue of the penis, thereby 
resulting in an erection.1 Every medication has side effects though, and this medication 
has a history of causing painless yet permanent visual symptoms.  These side effects are 
involved in the activation and modulation of the phototransduction cascade in retinal 
cone and rod cells.2 Since the introduction of this medication 10 years ago, there have 
been a number of reports of patients developing acute monocular visual loss due to 
nonarteritic anterior ischemic optic neuropathy (NAION) within hours of ingesting a 
PDE-5 inhibitor.3 Subsequently, the vision loss and color perception changes are 
permanent and develop into a rare disorder of NAION. 
NAION is a monocular defect and is caused by rapid ischemia to the optic nerve. 
It is related to the compromised circulation through the short posterior ciliary arteries due 
to episodes of hypotension and underlying vascular disease.4 The lack of oxygen causes 
acute vision loss, that progresses over time, leading to permanent optic nerve destruction.  
This destruction is troubling and several case reports have shown a correlation between 
PDE-5 inhibitor use and NAION. Although, there is some research on this topic, it is of 
low quality and, further research should be done to answer the question; can PDE-5 
inhibitors increase the risk of developing NAION in males with erectile dysfunction? 
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METHODS 
 An exhaustive literature search using MEDLINE-Ovid, MEDLINE-PubMed, 
CINAHL, ClinicalKey, and Web of Science was conducted. The following search words 
were used: “PDE-5 inhibitors,” “ischemic optic neuropathy,” and “NAION.”  Several 
background articles were used and eligibility criteria were applied to compile this paper. 
Included were studies that evaluated the correlation between males with erectile 
dysfunction who used PDE-5 inhibitors and the onset of NAION. Studies were excluded 
if they were not human trials or were not published in the English language.  
RESULTS 
 The initial research yielded 25 articles to review however, after screening these 
results and using the eligibility criteria, there were only one observational study5 and two 
case review articles6, 7 reviewed (see Table 1).  
Campbell et al  
 
This was the observational study1 performed in 2015 and was a blind review of 
records from102 ophthalmology centers in the United States and Europe. The authors 
wanted to look at each NAION case’s PDE-5 inhibitor exposure immediately prior to the 
onset of vision loss. They used a case-crossover design in which each case subject serves 
as his own control. This study was well designed to address whether the use of PDE-5 
inhibitors is associated with the onset of acute NAION, and where the timing of onset can 
be identified by the patient.5  
They classified the cases as definite, possible, or not NAION. The control 
window time prior to acute NAION onset was 30 days, and each window was 1 day in 
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length. The exposure status of the day prior to acute NAION onset (the case window) was 
compared with the exposure status of the 29 1-day periods prior to the case windows. A 
window was considered exposed if any part of it fell within 5 half-lives of ingestion of a 
PDE-5 inhibitor. Five half-lives equate to 1 day for Viagra usage and 4 days for Cialis 
usage.5   
The total of 673 potential cases of acute NAION were enrolled, 81 subjects 
reported exposure to PDE-5 inhibitors in the 2months prior to NAION symptom onset, 
and 592 subjects were enrolled as unexposed. The subjects provided their information via 
telephone interviews. If the subjects reported PDE-5 inhibitor use during the 60days prior 
to onset, they completed a telephone interview with the Study Call Center. The subjects 
were asked to recall dates of use and the specific PDE-5 inhibitor product. Furthermore, 
they needed to provide their average weekly frequency of medication usage and any 
unusual days of usage. During the phone interviews 5 out of the 81 exposed cases were 
confirmed to not being exposed during the 60days prior to onset. Of the 76 subjects left, 
48 were adjudicated as definite NAION cases, 24 were possible cases, and 4 were as non-
cases. There were 43 of the 48 definite cases who were exposed on at least 1 day, but not 
all of the 30days prior to onset; these cases were used in the primary analysis.1  
The authors found that in the definite NAION cases the OR were larger in the 
subjects <65 years (OR = 2.44), with a history of hypertension (OR = 2.41), with no 
history of hyperlipidemia (OR = 2.64), with no history of smoking (OR = 2.90), with no 
concomitant use of agents acting on the renin-angiotensin system (OR = 2.54), and with 
no concomitant use of aspirin (OR = 2.85).  As a result this study concluded that there 
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was an approximately twofold increased risk of acute NAION within 5 half-lives of PDE-
5 inhibitor use.1 
Pomeranz et al (2005) 
 
 This case review article6 was performed in 2005. The University of Minnesota 
reviewed the medical records of 7 patients whom developed NAION after ingestion of 
sildenafil (Viagra). These patients were aged between 50 and 69 years, and had typical 
features of NAION within 36hours of ingestion of PDE-5 inhibitors. All of the patients 
presented with blurred vision and loss of visual field, and in some cases the loss of visual 
acuity progressed over days or weeks. Furthermore, these patients had at least one 
arteriosclerotic risk factor (see Table 2).6  
Pomeranz et al (2002) 
 
This is the other case review article7 by the same author and was performed in 
2002. Five patients were identified as developing NAION after ingestion of sildenafil 
(Viagra) from the medical records of 4 neuro-ophthalmologists.  The authors of this case 
review gave attention to the time of development of ocular symptoms after ingestion of 
medication, visual acuity, pupillary examination, as well as a follow-up examination. 
These medical records were retrospectively reviewed in a non-masked manner.7  
Four of the 5 patients reported loss of vision in the affected eye within a short 
period of time (minutes to hours) after oral ingestion of the medication. Additionally, 
these 4 patients had no documented vascular risk factors; however, one case had a 
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previous episode of NAION. Documented visual acuity and symptoms, at presentation, 
were variable (see Table 2).7 
DISCUSSION 
 By integrating the results from these 3 articles,5-7 the consensus was that there is a 
possible linkage between the ingestion of PDE-5 inhibitors and the development of acute 
NAION. The observation study and case reviews, although a small sample size, showed a 
strong correlation between the medication and the disease progression, with the 
observation study 5 demonstrating a twofold increase in the risk. The patients developed 
visual loss within 1 to 2 days, after ingestion of the medication. These developed 
symptoms are damaging and permanent to the optic nerve.  
 In appraising the current evidence, there were a few limitations that presented 
during the research. One of the major concerns was in the variability across the articles. 
Although 25 articles appeared in the keyword search, only 1 observational study and 2 
case review articles meet the inclusion criteria. Also, the small sample size provided 
limitations. The observational study5 only used 43 cases and the case reviews6,7 used a 
total of 12 patients. Furthermore, the observational study5 used telephone interviews for 
follow-up information, instead of an actual examination. These telephone interviews 
relied heavily on the patient’s recall of drug ingestion. Although, these articles have their 
limitations the evidence is brought to light and further research is necessary to provide 
better care for the patients.  
 While, the correlation between PDE-5 inhibitors and the development of NAION 
is lacking good quality clinical research, additional investigation on this subject can 
better equip clinicians when prescribing this drug class.  While the research is still in its 
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early stages, researchers should put more into exploring side effects especially if they 
want to better inform patients. If the research, indeed, finds a correlation, then perhaps 
further research into other products with fewer side effects would gain momentum.  
Nevertheless, further research will enable providers to counsel and educate their patients 
on the more harmful and permanent side effects of PDE-5 inhibitors.  
CONCLUSION 
 PDE-5 inhibitors are the choice of treatment for erectile dysfunction and are, very 
effective for treating this disease. Given the current suggestion of a link between PDE-5 
inhibitor use and acute NAION though, further research is needed. There is a lack of 
clinical trials, which are essential in proving this correlation.  Further research will allow 
providers to be more cognizant when prescribing this medication. Additionally, it will 
make patients more aware of the side effects and help them to understand when to seek 
help to prevent supplementary damage.  
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Table 1. GRADE Assessment: Characteristics of 
Reviewed Studies 
Design 
Included 
Outcomes 
Downgrade Criteria 
Quality 
Limitations Indirectness Imprecision Inconsistency 
Publication 
bias likely 
Campbell et al (2015) 
 
Observational 
 
PDE5 inhibitor 
ingestion, exposure 
period, risk of acute 
NAION 
Seriousa Not serious Serious,b Not serious  
 
 Unlikely 
 
Very 
low 
Pomeranz et al (2005)6 
Case Series 
Pre-existing risk, 
exposure period 
Very 
seriousc 
Not serious  Serious,b Not serious 
 
Unlikely 
 
Very 
low 
Pomeranz et al (2002)7 
Case Series 
Transient visual 
changes, NAION, 
PDE5 inhibitor 
ingestion 
Very 
seriousc 
Not serious  Serious,b Not serious 
 
Unlikely 
 
Very 
low 
a High risk of recall bias 
b Small sample size 
c Lack of control group and blinding  
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Table 2: Case Review Summary 
Reference Case Age  Co-
morbidity 
Symptoms Onset Eye Exam 
duration 
Final 
Visual 
Acuity 
Defect 
Pomeranz 
et al 
(2005)6 
1 59 ED, skin 
CA, HA, 
depression 
Bright 
colors, 
vision loss 
Hours OU 1year HM 
OS, LP 
OD 
Pale 
optic 
disc OS 
 2 58 ED, 
elevated 
cholesterol  
Loss of 
vision OD 
Immediate OD 2mon HM  Pale 
optic 
disc  
 3 67 HTN, 
seizure 
Loss of 
vision OD 
24hours OD  2 years 20/200 Depress 
VF OD 
 4 50 Not 
mentioned 
Worsen 
vision OS 
30hours OS 4mon CF Pallor 
optic 
disc 
 5 69 HTN, a-fib, 
ED, CA 
(prostate) 
Loss of 
vision OS 
24hours OS  6mon 20/125 Pale 
optic 
disc 
 6 66 DM, HTN, 
elevated 
cholesterol 
Loss of 
vision OD 
36hours OD 30mon 20/30 Pale 
optic 
disc 
 7 60 Elevated 
cholesterol 
Shade 
coming 
down 
Next AM OD 3mon 20/20 Pallor 
ON 
Pomeranz 
et al 
(2002)7 
1 52 Prostate 
CA, 
Crohn’s  
Blurry 
vision  
1hour OS 9mon 20/20 Pallor 
ON 
 2 69 Elevated 
cholesterol  
Painless 
vision loss  
45mins OD 3wks  20/80 Pallor 
ON  
 3 42 None Blurry 
vision  
12hours OD 2mon 20/200 Pale ON 
 4 62 NAION in 
1997 
Decrease 
vision 
Unclear OD 3mon 20/50 Pallor 
ON 
 5 59 DM, 
CAD 
 Several 
hours 
OD 1wk 20/25 Inferior 
VF 
defect 
KEY: ON (optic nerve), CA (cancer), OU (both eyes), OS (left eye), OD (right eye), DM 
(diabetes mellitus), CAD (coronary artery disease), VF (visual field), HA (headache), 
HM (hand motion), LP (light perception), HTN (hypertension), CF (count fingers) 
